Try our beta test site

Comparative Study Between Hyperbaric Therapy and Intravesical Dimethyl Sulfoxide Instillation for Interstitial Cystitis

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified February 2010 by Assaf-Harofeh Medical Center.
Recruitment status was:  Recruiting
Information provided by:
Assaf-Harofeh Medical Center Identifier:
First received: January 10, 2010
Last updated: April 4, 2011
Last verified: February 2010
The purpose of this study is to compare the efficacy of hyperbaric oxygen therapy (HBOT) to intravesical Dimethyl Sulfoxide (DMSO) instillation for the treatment of patients who suffers from Interstitial Cystitis / Painful bladder syndrome.

Condition Intervention
Interstitial Cystitis
Other: Hyperbaric Oxygen Therapy
Drug: DMSO

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Comparison Between Hyperbaric Oxygen Therapy (HBOT) and Intravesical Dimethyl Sulfoxide (DMSO) Instillation for the Treatment of Interstitial Cystitis - a Prospective, Randomized Cross-over Trial

Resource links provided by NLM:

Further study details as provided by Assaf-Harofeh Medical Center:

Primary Outcome Measures:
  • Subjective improvement will be assessed by several questionnaires: the Oleary Sant symptom index score, bladder diary, 1-10 visual analogue scale for pain, PSQ4 questionnaire [ Time Frame: 1-4 weeks post treatment ]

Secondary Outcome Measures:
  • Objective improvement will be assessed by urodynamic test. The following parameters will be addressed: cystometric capacity, 1st sensation, normal sensation [ Time Frame: 1-4 weeks post treatment ]

Estimated Enrollment: 60
Study Start Date: February 2010
Estimated Study Completion Date: July 2015
Estimated Primary Completion Date: March 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Intravesical DMSO instillation
50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
Drug: DMSO
50 mls of 50% DMSO instilled once a week to the urinary bladder for 12 consecutive weeks.
Other Name: dimethyl sulfoxide
Experimental: Hyperbaric Oxygen Therapy (HBOT)
Overall 60 treatments (5 days per weeks for 12 weeks). 90 minutes every session. Pressure of 2 atm. Inhalation of 100% oxygen.
Other: Hyperbaric Oxygen Therapy
60 treatments (12 weeks - 5 days a week) of hyperbaric (pressure of 2 atmospheres) with 100% oxygen inhalation.
Other Names:
  • HBOT
  • Hyperbaric chamber
  • Hyperbaric therapy

Detailed Description:

Interstitial cystitis / painful bladder syndrome (IC/PBS) presents as a pelvic pain condition associated with urinary urgency and frequency. These symptoms impair significantly the patient's quality of life. The etiology is yet not obvious. The current acceptable theory is injury or dysfunction of the Mucus (Glycosaminoglycans) layer that covers the inner surface of the urinary bladder. Abnormal diffusion of toxins from the urine to the walls of the bladder leads to inflammation, pain and scarring.

Many types of treatments were described but most of them were not evaluated in well designed randomized controlled studies. For now, there is no one single treatment that gives good outcome to every patient. Therefore, the treatment of patients with IC/PBS is challenging. In this study, we will compare the efficacy of hyperbaric oxygen therapy (HBOT) to intravesical dimethyl sulfoxide (DMSO) instillation for the treatment of patients who suffers from IC/PBS.

Patients with IC (NIDDK criteria) will be randomized to have either DMSO instillation or HBOT.

Before and after treatments the patients will fill out questionnaires (O'Leary-Sant Interstitial Cystitis Symptom and Problem Index), visual analogue scale for pain and bladder diaries. In addition, urodynamics will be performed before and after treatments. In case of incomplete symptoms remission, patients will be crossed over to have the other treatment.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • NIDDK diagnosis of interstitial cystitis

Exclusion Criteria:

  • Previous treatment of hyperbaric therapy
  • Contraindication for hyperbaric therapy (mid-ear pathology, abnormal chest X-ray, Claustrophobia, pregnancy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01069263

Assaf Harofe Medical Center
Zeriffin, Israel, 70300
Sponsors and Collaborators
Assaf-Harofeh Medical Center
Principal Investigator: Kobi Stav, MD Assaf Harofe Medical Center
  More Information

Additional Information:
Responsible Party: Kobi Stav, Assaf-Harofeh Medical Center Identifier: NCT01069263     History of Changes
Other Study ID Numbers: 04/10 
Study First Received: January 10, 2010
Last Updated: April 4, 2011

Keywords provided by Assaf-Harofeh Medical Center:
Interstitial cystitis
Painful bladder syndrome
Chronic pelvic pain
Hyperbaric oxygen therapy

Additional relevant MeSH terms:
Cystitis, Interstitial
Urinary Bladder Diseases
Urologic Diseases
Dimethyl Sulfoxide
Cryoprotective Agents
Protective Agents
Physiological Effects of Drugs
Free Radical Scavengers
Molecular Mechanisms of Pharmacological Action processed this record on February 20, 2017